1Palandri F, Castagnetti F, Alimena G, et al. The long-term dura- bility of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up [ J]. Haematologica,2009,94(2) :205-212.
2Druker B J, Guilhot F, OBrien SG, et al. Five-year follow-up of pa- tients receiving imatinib for chronic myeloid leukemia[ J]. N Engl J Med ,2006,355 ( 23 ) :2408-2417.
3Ye JY, Chan GC, Yang M, et al. platelet-derived growth factor en- hance platelet recovery in a murine model of radiation-induced thrombocytopenia and reduce apoptosis in megakaryocytes via its receptors and the PI3-k/Akt pathway[J].Haematologica,2010, 95 (10) : 1745-1735.
4Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions [ J ]. Clin Pharmacol T- her, 1981,30(2) :239-245.
